A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed or Refactory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Trial Profile

A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed or Refactory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; AT 101
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018 as reported by ClinicalTrials.gov record.
    • 27 Jul 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018 as reported by ClinicalTrials.gov record.
    • 15 Apr 2015 Planned number of patients changed from 63 to 60 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top